These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11880710)

  • 1. Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration.
    Booton R; Thatcher N
    Curr Opin Oncol; 2002 Mar; 14(2):191-8. PubMed ID: 11880710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival.
    Lilenbaum RC; Langenberg P; Dickersin K
    Cancer; 1998 Jan; 82(1):116-26. PubMed ID: 9428487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms.
    Socinski MA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4210s-4214s. PubMed ID: 15217960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
    Langer F; Helsberg K; Schütte WH; Leschinger MI
    Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First- and second-line therapy for advanced nonsmall cell lung cancer.
    Sculier JP; Moro-Sibilot D
    Eur Respir J; 2009 Apr; 33(4):915-30. PubMed ID: 19336594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
    Langer CJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal duration of chemotherapy in advanced non-small cell lung cancer.
    Lustberg MB; Edelman MJ
    Curr Treat Options Oncol; 2007 Feb; 8(1):38-46. PubMed ID: 17634834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic overview of chemotherapy effects in non-small cell lung cancer.
    Sörenson S; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):327-39. PubMed ID: 11441939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Older age, poor performance status and major comorbidities: how to treat high-risk patients with advanced nonsmall cell lung cancer.
    Aggarwal C; Langer CJ
    Curr Opin Oncol; 2012 Mar; 24(2):130-6. PubMed ID: 22314616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined-modality treatment of locally advanced non-small cell lung cancer: incorporation of novel chemotherapeutic agents.
    Belani CP; Ramanathan RK
    Chest; 1998 Jan; 113(1 Suppl):53S-60S. PubMed ID: 9438691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a meta-analysis and the Cancer and Leukemia Group B randomized trial.
    Lilenbaum RC; List M; Desch C
    Semin Oncol; 1999 Oct; 26(5 Suppl 15):52-4. PubMed ID: 10566612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
    Herbst RS
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized chemotherapy for elderly patients with nonsmall cell lung cancer.
    Gridelli C; Maione P; Barletta E
    Curr Opin Oncol; 2002 Mar; 14(2):199-203. PubMed ID: 11880711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.
    Gridelli C; Aapro M; Ardizzoni A; Balducci L; De Marinis F; Kelly K; Le Chevalier T; Manegold C; Perrone F; Rosell R; Shepherd F; De Petris L; Di Maio M; Langer C
    J Clin Oncol; 2005 May; 23(13):3125-37. PubMed ID: 15860872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in chemotherapy for advanced non-small cell lung cancer.
    Raez LE; Lilenbaum R
    Curr Opin Oncol; 2006 Mar; 18(2):156-61. PubMed ID: 16462185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future beyond platinum for the treatment of advanced non-small cell lung cancer.
    Dragnev KH; Rigas JR
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):73-6. PubMed ID: 10585012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scheduling of chemotherapy and radiotherapy in locally advanced non-small cell lung cancer.
    Bishop JF
    Lung Cancer; 1995 Jun; 12 Suppl 2():S53-61. PubMed ID: 7551950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy for advanced non-small cell lung cancer: standards.
    Manegold C
    Lung Cancer; 2001 Dec; 34 Suppl 2():S165-70. PubMed ID: 11720760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.